These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25253665)

  • 21. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
    Pitisuttithum P; Nitayaphan S; Chariyalertsak S; Kaewkungwal J; Dawson P; Dhitavat J; Phonrat B; Akapirat S; Karasavvas N; Wieczorek L; Polonis V; Eller MA; Pegu P; Kim D; Schuetz A; Jongrakthaitae S; Zhou Y; Sinangil F; Phogat S; Diazgranados CA; Tartaglia J; Heger E; Smith K; Michael NL; Excler JL; Robb ML; Kim JH; O'Connell RJ; Vasan S;
    Lancet HIV; 2020 Apr; 7(4):e238-e248. PubMed ID: 32035516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.
    Goepfert PA; Horton H; McElrath MJ; Gurunathan S; Ferrari G; Tomaras GD; Montefiori DC; Allen M; Chiu YL; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Keefer MC; Baden LR; Corey L;
    J Infect Dis; 2005 Oct; 192(7):1249-59. PubMed ID: 16136469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
    Omosa-Manyonyi G; Mpendo J; Ruzagira E; Kilembe W; Chomba E; Roman F; Bourguignon P; Koutsoukos M; Collard A; Voss G; Laufer D; Stevens G; Hayes P; Clark L; Cormier E; Dally L; Barin B; Ackland J; Syvertsen K; Zachariah D; Anas K; Sayeed E; Lombardo A; Gilmour J; Cox J; Fast P; Priddy F
    PLoS One; 2015; 10(5):e0125954. PubMed ID: 25961283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
    Kibuuka H; Kimutai R; Maboko L; Sawe F; Schunk MS; Kroidl A; Shaffer D; Eller LA; Kibaya R; Eller MA; Schindler KB; Schuetz A; Millard M; Kroll J; Dally L; Hoelscher M; Bailer R; Cox JH; Marovich M; Birx DL; Graham BS; Michael NL; de Souza MS; Robb ML
    J Infect Dis; 2010 Feb; 201(4):600-7. PubMed ID: 20078213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
    Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
    PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.
    Leroux-Roels G; Bourguignon P; Willekens J; Janssens M; Clement F; Didierlaurent AM; Fissette L; Roman F; Boutriau D
    Clin Vaccine Immunol; 2014 Mar; 21(3):302-11. PubMed ID: 24391139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.
    O'Connell RJ; Excler JL; Polonis VR; Ratto-Kim S; Cox J; Jagodzinski LL; Liu M; Wieczorek L; McNeil JG; El-Habib R; Michael NL; Gilliam BL; Paris R; VanCott TC; Tomaras GD; Birx DL; Robb ML; Kim JH
    J Infect Dis; 2016 Jun; 213(12):1946-54. PubMed ID: 26908741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy.
    Jin X; Ramanathan M; Barsoum S; Deschenes GR; Ba L; Binley J; Schiller D; Bauer DE; Chen DC; Hurley A; Gebuhrer L; El Habib R; Caudrelier P; Klein M; Zhang L; Ho DD; Markowitz M
    J Virol; 2002 Mar; 76(5):2206-16. PubMed ID: 11836398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.
    Thongcharoen P; Suriyanon V; Paris RM; Khamboonruang C; de Souza MS; Ratto-Kim S; Karnasuta C; Polonis VR; Baglyos L; Habib RE; Gurunathan S; Barnett S; Brown AE; Birx DL; McNeil JG; Kim JH;
    J Acquir Immune Defic Syndr; 2007 Sep; 46(1):48-55. PubMed ID: 17909315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
    Priddy FH; Brown D; Kublin J; Monahan K; Wright DP; Lalezari J; Santiago S; Marmor M; Lally M; Novak RM; Brown SJ; Kulkarni P; Dubey SA; Kierstead LS; Casimiro DR; Mogg R; DiNubile MJ; Shiver JW; Leavitt RY; Robertson MN; Mehrotra DV; Quirk E;
    Clin Infect Dis; 2008 Jun; 46(11):1769-81. PubMed ID: 18433307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers.
    Mehendale S; Thakar M; Sahay S; Kumar M; Shete A; Sathyamurthi P; Verma A; Kurle S; Shrotri A; Gilmour J; Goyal R; Dally L; Sayeed E; Zachariah D; Ackland J; Kochhar S; Cox JH; Excler JL; Kumaraswami V; Paranjape R; Ramanathan VD
    PLoS One; 2013; 8(2):e55831. PubMed ID: 23418465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.
    Chirenje ZM; Laher F; Dintwe O; Muyoyeta M; deCamp AC; He Z; Grunenberg N; Laher Omar F; Seaton KE; Polakowski L; Woodward Davis AS; Maganga L; Baden LR; Mayer K; Kalams S; Keefer M; Edupuganti S; Rodriguez B; Frank I; Scott H; Stranix-Chibanda L; Gurunathan S; Koutsoukos M; Van Der Meeren O; DiazGranados CA; Paez C; Andersen-Nissen E; Kublin J; Corey L; Ferrari G; Tomaras G; McElrath MJ
    J Infect Dis; 2024 Aug; 230(2):e405-e415. PubMed ID: 37795976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).
    García F; Bernaldo de Quirós JC; Gómez CE; Perdiguero B; Nájera JL; Jiménez V; García-Arriaza J; Guardo AC; Pérez I; Díaz-Brito V; Conde MS; González N; Alvarez A; Alcamí J; Jiménez JL; Pich J; Arnaiz JA; Maleno MJ; León A; Muñoz-Fernández MA; Liljeström P; Weber J; Pantaleo G; Gatell JM; Plana M; Esteban M
    Vaccine; 2011 Oct; 29(46):8309-16. PubMed ID: 21907749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.
    Gray GE; Mayer KH; Elizaga ML; Bekker LG; Allen M; Morris L; Montefiori D; De Rosa SC; Sato A; Gu N; Tomaras GD; Tucker T; Barnett SW; Mkhize NN; Shen X; Downing K; Williamson C; Pensiero M; Corey L; Williamson AL
    Clin Vaccine Immunol; 2016 Jun; 23(6):496-506. PubMed ID: 27098021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
    Keefer MC; Gilmour J; Hayes P; Gill D; Kopycinski J; Cheeseman H; Cashin-Cox M; Naarding M; Clark L; Fernandez N; Bunce CA; Hay CM; Welsh S; Komaroff W; Hachaambwa L; Tarragona-Fiol T; Sayeed E; Zachariah D; Ackland J; Loughran K; Barin B; Cormier E; Cox JH; Fast P; Excler JL
    PLoS One; 2012; 7(8):e41936. PubMed ID: 22870265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.
    Eller MA; Slike BM; Cox JH; Lesho E; Wang Z; Currier JR; Darden JM; Polonis VR; Vahey MT; Peel S; Robb ML; Michael NL; Marovich MA
    PLoS One; 2011; 6(9):e24254. PubMed ID: 21949699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers.
    Richert L; Hue S; Hocini H; Raimbault M; Lacabaratz C; Surenaud M; Wiedemann A; Tisserand P; Durier C; Salmon D; Lelièvre JD; Chêne G; Thiébaut R; Lévy Y;
    AIDS; 2013 Jun; 27(9):1421-31. PubMed ID: 23759749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults.
    Kalams SA; Parker S; Jin X; Elizaga M; Metch B; Wang M; Hural J; Lubeck M; Eldridge J; Cardinali M; Blattner WA; Sobieszczyk M; Suriyanon V; Kalichman A; Weiner DB; Baden LR;
    PLoS One; 2012; 7(1):e29231. PubMed ID: 22242162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
    Guardo AC; Gómez CE; Díaz-Brito V; Pich J; Arnaiz JA; Perdiguero B; García-Arriaza J; González N; Sorzano COS; Jiménez L; Jiménez JL; Muñoz-Fernández MÁ; Gatell JM; Alcamí J; Esteban M; López Bernaldo de Quirós JC; García F; Plana M;
    PLoS One; 2017; 12(10):e0186602. PubMed ID: 29065142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.